jetcityimage/iStock Editorial via Getty Images
Eli Lilly (LLY) announced on Friday that the FDA has approved a label expansion for its blockbuster GLP-1 drug Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events such as stroke in adults with type 2 diabetes.
Accordingly, the
